The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. TG Therapeutics Inc.’s current trading price is -72.81% away from its 52-week high, while its distance from the 52-week low is 99.59%. The stock’s price range for this period has been between $4.86 and $35.67 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 2.51 million for the day, a number notably lower than the average daily volume of 4.98 million over the last three months.
At present, TG Therapeutics Inc. (TGTX) has a stock price of $9.70. In the previous session, the stock saw a rise, peaking at $10.311 after an opening price of $10.19. The day’s lowest price was $9.97, and it closed at $10.14.
TG Therapeutics Inc. ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $35.67 on 05/04/23, while the lowest value for the same period was recorded at $4.86 on 10/21/22.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
TG Therapeutics Inc. (TGTX) has experienced a quarterly decline of -62.21% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.47B and boasts a workforce of 244 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 20.81, with a change in price of -12.71. Similarly, TG Therapeutics Inc. recorded 4,676,658 in trading volume during the last 100 days, posting a change of -56.81%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for TGTX stands at 2.41. Similarly, the long-term debt-to-equity ratio is also 2.41.
TGTX Stock Stochastic Average
TG Therapeutics Inc.’s raw stochastic average for the past 50 days is presently 2.89%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 14.95%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 13.05% and 14.35%, respectively.
TGTX Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Year to date metric has recorded a loss of -18.01%.However, over the last six months, we can see a stronger performance of -34.42%. Over the last 30 days, the price of TGTX has leaped by -6.64%. And in the last five days, it has fallen by -8.66%.